
Sanofi
Sanofi (SNY)
Price
Market cap
Next catalystExpected Q4 2026Sarclisa (isatuximab-irfc) · Phase 3 dataCompany source ↗
Cash
Chart & Events
Core Clinical
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Background, answer, next evidence
Clinical
Upcoming clinical milestones
Other pipelines
Partner / License out
Approved / commercial
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
History / paused
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Financial position
Company funding outlook
Upcoming milestones
Financial history
Annual trends
| Reported item | |||||
|---|---|---|---|---|---|
Reported shares and borrowings
Ownership and institutions
| Status | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|